Molecular Diagnosis & Therapy

, Volume 14, Issue 4, pp 215–222 | Cite as

Human Papillomavirus DNA Testing for Cervical Cancer Screening

Practical Aspects in Developing Countries
Review Article


Cervical cancer is the second most common cancer in women worldwide, and the most common cause of death from cancer in women in the developing world. Cervical cancer represents the only gynecologic cancer that can be prevented through regular screening. Although there are established screening programs in the Western world that have effectively reduced the burden of cervical cancer, these programs have relied on insensitive screening technologies that depend on the long preinvasive phase of cervical carcinogenesis. The developing world faces specific additional challenges in implementing a successful cervical cancer screeing program.

The association between cervical cancers and human papillomavirus (HPV) make testing for the presence of HPV DNA a valuable screening tool. This review focuses on practical aspects of the implementation and delivery of HPV testing as the primary cervical cancer screening strategy in the developing world, and attempts to offer some solutions to the real-world challenges faced in these regions.


  1. 1.
    Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Sankaranarayanan R, Wesley R, Somanathan T, et al. Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. Cancer 1998; 83: 2150–6PubMedCrossRefGoogle Scholar
  3. 3.
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause ofinvasive cervical cancer worldwide. J Pathol 1999; 189:12–9PubMedCrossRefGoogle Scholar
  4. 4.
    Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247–9PubMedCrossRefGoogle Scholar
  5. 5.
    Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER cancer statistics review 1975–2007. Bethesda (MD): National Cancer Institute, 2010 Jun 30 [online]. Available from URL: [Accessed 2010 Aug 3]
  6. 6.
    Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941; 42: 193–206Google Scholar
  7. 7.
    Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095–101PubMedCrossRefGoogle Scholar
  8. 8.
    Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398–406PubMedCrossRefGoogle Scholar
  9. 9.
    Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385–94PubMedCrossRefGoogle Scholar
  10. 10.
    zur Hausen H. Natural history and carcinogenesis of cervical cancer: the global picture [keynote lecture]. 2010 Annual Meeting, European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2010 Feb 17–20; Monte CarloGoogle Scholar
  11. 11.
    Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63–73PubMedCrossRefGoogle Scholar
  12. 12.
    Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101–5PubMedCrossRefGoogle Scholar
  13. 13.
    Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157–64PubMedCrossRefGoogle Scholar
  14. 14.
    Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781–9PubMedCrossRefGoogle Scholar
  15. 15.
    Belinson JL, Hu S, Niyazi M, et al. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. Int J Cancer 2010; 127: 1151–7PubMedCrossRefGoogle Scholar
  16. 16.
    Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 439–44PubMedCrossRefGoogle Scholar
  17. 17.
    Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province Cervical Cancer Screening Study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer 2003; 13: 819–26PubMedCrossRefGoogle Scholar
  18. 18.
    Belinson JL, Hui D, Wang GP, et al. Evaluation of the POI/NIH cervico-vaginal self-sampler for HPV from the SHENCCAST II trial [abstract]. 4th Biennial Meeting, Asia Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN); 2010 Mar 26–28; New DelhiGoogle Scholar
  19. 19.
    Tisci S, Shen YH, Fife D, et al. Patient acceptance of self-sampling for human papillomavirus in rural China. J Low Genit Tract Dis 2003; 7: 107–16PubMedCrossRefGoogle Scholar
  20. 20.
    Nieves-Arriba L, Enerson C, Belinson S, et al. Mexican Cervical Cancer Screening Study II: acceptability of a new self-sampling device [abstract no. 43]. 41st Annual Meeting, Society Of Gynecologic Oncologists; 2010 Mar 14–17; San Francisco (CA)Google Scholar
  21. 21.
    Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–97PubMedCrossRefGoogle Scholar
  22. 22.
    Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579–88PubMedCrossRefGoogle Scholar
  23. 23.
    Cuzick J, Szarewski A, Mesher D, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology: results from the Hammersmith Study. Int J Cancer 2008; 122: 2294–300PubMedCrossRefGoogle Scholar
  24. 24.
    Shi JF, Belinson JL, Zhao FH, et al. Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. Am J Epidemiol 2009; 170: 708–16PubMedCrossRefGoogle Scholar
  25. 25.
    Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754PubMedCrossRefGoogle Scholar
  26. 26.
    Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677–84PubMedCrossRefGoogle Scholar
  27. 27.
    Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929–36PubMedCrossRefGoogle Scholar
  28. 28.
    Söderlund-Strand A, Dillner J, Carlson J. High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem 2008; 54(1): 86–92PubMedCrossRefGoogle Scholar
  29. 29.
    Chirenje ZM, Rusakaniko S, Akino V, et al. A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia. J Obstet Gynaecol 2001; 21: 617–21PubMedCrossRefGoogle Scholar
  30. 30.
    Chamot E, Kristensen S, Stringer JS, et al. Are treatments for cervical pre-cancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review. BMC Womens Health 2010; 10: 11PubMedCrossRefGoogle Scholar
  31. 31.
    Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998; 92: 737–44PubMedCrossRefGoogle Scholar
  32. 32.
    Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2010; (6): CD001318Google Scholar
  33. 33.
    Wulan N, Rasool N, Belinson SE, et al. Study of the diagnostic efficacy of realtime optical coherence tomography as an adjunct to unaided visual inspection with acetic acid for the diagnosis of preinvasive and invasive neoplasia of the uterine cervix. Int J Gynecol Cancer 2010; 20: 422–7PubMedCrossRefGoogle Scholar
  34. 34.
    Belinson JL, Pretorius RG, Enerson C, et al. The Mexican Cervical Cancer Screening Trial: self-sampling for human papillomavirus with unaided visual inspection as a secondary screen. Int J Gynecol Cancer 2009; 19: 27–32PubMedCrossRefGoogle Scholar
  35. 35.
    Day SP, Hudson A, Mast A, et al. Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study. J Clin Virol 2009; 45Suppl. 1: S63–72PubMedCrossRefGoogle Scholar
  36. 36.
    Thai H, Rangwala S, Gay T, et al. An HPV 16,18, and 45 genotyping test based on Hybrid Capture technology. J Clin Virol 2009; 45Suppl. 1: S93–7PubMedCrossRefGoogle Scholar
  37. 37.
    Kraus I, Molden T, Holm R, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 2006; 44: 1310–7PubMedCrossRefGoogle Scholar
  38. 38.
    Global Polio Eradication Initiative. The history [online]. Available from URL: [Accessed 2010 Jul 27]

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Preventive Oncology International, Inc.Cleveland HeightsUSA

Personalised recommendations